Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant by Salomoni, Paolo et al.
 
1995
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/06/1995/13 $2.00
Volume 187, Number 12, June 15, 1998 1995–2007
http://www.jem.org
 
Expression of Constitutively Active Raf-1 in the
Mitochondria Restores Antiapoptotic and Leukemogenic
Potential of a Transformation-deﬁcient BCR/ABL Mutant
 
By Paolo Salomoni,
 
*
 
‡
 
 Mariusz A. Wasik,
 
§
 
 Richard F. Riedel,
 
*
 
Krzysztof Reiss,
 
*
 
 John K. Choi,
 
§
 
 Tomasz Skorski,
 
*
 
and Bruno Calabretta
 
*
 
From the 
 
*
 
Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson 
University, Philadelphia, Pennsylvania 19107; the 
 
‡
 
Department of Biomedical Sciences, University of 
Modena, 41100 Modena, Italy; and the 
 
§
 
Department of Pathology and Laboratory Medicine, 
University of Pennsylvania, Philadelphia, Pennsylvania 19102
 
Summary
 
The oncogenic BCR/ABL protein protects hematopoietic cells from apoptosis induced by
growth factor deprivation, but the mechanisms are only partially understood. A BCR/ABL
mutant lacking amino acids 176–426 in the BCR domain (p185
 
D
 
BCR) failed to protect inter-
leukin 3–deprived 32Dcl3 myeloid precursor cells from apoptosis, although it possessed ty-
rosine kinase activity and was capable of activating the Ras-Raf-MAP kinase pathway. Com-
pared to p185 wild-type transfectants, p185
 
D
 
BCR-transfected cells showed markedly reduced
levels of Bcl-2 and expressed the hypophosphorylated, proapoptotic form of BAD. Bcl-2 ex-
pression in the mitochondrial fraction of p185
 
D
 
BCR cells was also markedly diminished and
mitochondrial RAF was undetectable. In p185
 
D
 
BCR cells transfected with a mitochondria-
targeted, constitutively active RAF (M-Raf) BAD was expressed in the hyperphosphorylated
form and released from the mitochondria into the cytosol. p185
 
D
 
BCR/M-Raf–transfected
cells were completely resistant to apoptosis induced by growth factor deprivation in vitro.
Moreover, constitutive expression of dominant-negative M-Raf (K375W) enhanced the sus-
ceptibility of 32Dcl3 cells expressing wild-type BCR/ABL to apoptosis. In severe combined
immunodeficiency (SCID) mice, p185
 
D
 
BCR/M-Raf double transfectants were leuke-
mogenic, whereas cells expressing only p185
 
D
 
BCR showed no leukemogenic potential. To-
gether, these data support the existence of a BCR/ABL-dependent pathway that leads to
expression of an active RAF in the mitochondria and promotes antiapoptotic and leukemia-
inducing effects of BCR/ABL.
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B
 
cr
 
/
 
abl
 
 is a chimeric oncogene generated from a chro-
mosomal translocation between chromosomes 9 and
22 (Philadelphia chromosome), which juxtaposes sequences
from the 
 
bcr
 
 gene with sequences upstream of the second
exon of 
 
c-abl. bcr
 
/
 
abl
 
 genes encode two proteins: p185,
which contains a smaller BCR portion (amino acids 1–426)
and is associated with acute lymphocytic leukemia (1), and
p210, which contains a larger BCR portion (amino acids
1–902 or –926) and is found in most cases of chronic myelog-
enous leukemia (CML
 
1
 
; reference 2). Both BCR/ABL chi-
meric proteins are constitutively active tyrosine kinases that
can transform fibroblasts and hematopoietic cells in culture
(3–5) and induce leukemia in mice (6, 7). The fused BCR
sequences activate the tyrosine kinase, actin binding, and
transforming functions of ABL. Activation of the ABL-
transforming function has been shown to require two dis-
tinct domains of BCR: domain 1 (amino acids 1–63) and
domain 2 (amino acids 176–242) (8). Sequences within the
first exon of BCR (amino acids 192–242 and 298–413)
have been implicated in the binding to the SH2 domain of
ABL (9), and the deletion of domain 2 of BCR has been
shown to decrease BCR/ABL-dependent transforming
ability (9). The region spanning amino acids 243–923 does
not seem to play a role in transformation, but is involved in
the stabilization of actin fibers (10). BCR/ABL tyrosine ki-
nase activity was recently shown to protect cells from apop-
 
1
 
Abbreviations used in this paper:
 
 AML, acute myelogenous leukemia; C,
cytoplasmic; COX, cytochrome oxidase; CML, chronic myelogenous
leukemia; DTT, dithiothreitol; HM, heavy membrane; LM, light mem-
brane; M, mitochondria-targeted; MAP, mitogen-activated protein;
MAPK, MAP kinase; MBP, myelin basic protein.
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tosis induced by various stimuli (11–13). The apoptotic
process can be subdivided into three functional phases: ini-
tiation, wherein the death-inducing stimulus is applied; the
effector phase, when the “decision to die” is made; and
degradation, when overall cell entropy precludes further
regulatory mechanisms and leads to the activation of meta-
bolic enzymes (14). Although it is not yet clear which of
these phases are affected by BCR/ABL, it has been shown
that BCR/ABL can regulate the expression of the antiapop-
totic gene bcl-2 (15, 16).
The bcl-2 gene, originally identified at the chromosomal
breakpoint of t(14;18)-carrying B cell lymphomas, is the
prototype of a growing family of apoptosis regulators con-
sisting of both inhibitors and promotors. Many of the pro-
teins belonging to this family are predominantly localized
in the outer mitochondrial membrane. Bcl-2 itself shows a
patchy distribution in contact areas between the outer and
inner mitochondrial membrane (17, 18), and the mito-
chondrial localization of Bcl-2 family proteins is necessary
for regulation of apoptosis (17, 19, 20). The ratio of antag-
onists (Bcl-2, Bcl-X
 
L
 
) and agonists (Bax, BAD, Bcl-X
 
S
 
) de-
termines, in part, how cells will respond to an apoptotic
stimulus (21, 22), but posttranslational modifications also
play a major role in the regulation of apoptosis. Bcl-2 can
be degraded by trypsin and chymotrypsin (23), and by
caspases (24). Serine phosphorylation of Bcl-2 induced by
treatment either with taxol, vinblastine, or vincristine has
been correlated with loss of Bcl-2 activity (25); on the
other hand, a recent study suggests that serine phosphoryla-
tion is an early event after IL-3 stimulation and is required
for the antiapoptosis function of Bcl-2 (26). BAD has also
been shown to be target of serine phosphorylation. In the
presence of IL-3, BAD becomes phosphorylated on serine
residues. Upon IL-3 withdrawal, BAD is unphosphorylated
and binds Bcl-X
 
L
 
 (20), thus inhibiting the survival-promot-
ing effects of Bcl-X
 
L
 
 (27). By contrast, the phosphorylated
form is sequestered in the cytoplasm by 14-3-3, a protein
which associates with many signaling molecules in a phos-
phoserine-dependent manner (28), but whose function in
mammalian cells in not yet understood.
Recent reports have shown that the Ras-Raf-mitogen-
activated protein (MAP) kinase pathway can play an im-
portant role in the regulation of the apoptotic process in
hematopoietic cells. Expression of oncogenic Ras protein
complemented the function of a mutant GM-CSF receptor
that failed to activate the Ras-Raf-MAP kinase pathway
and was unable to promote cell survival (29); expression of
a dominant-negative Ras induced apoptotic cell death in
BCR/ABL-expressing cells (30).
Active forms of a downstream effector of Ras, the
serine-threonine kinase Raf-1, have also been shown to
prevent apoptosis in hematopoietic cells (31). Moreover,
inhibition of Raf-1 by cyclic AMP agonists in v-ABL–
transformed cells or by antisense oligonucleotides in cells
expressing BCR/ABL has been shown to induce apoptosis
(32, 33). The antiapoptotic effects of Raf-1 might be, in
part, mediated by the reported physical interaction be-
tween Raf-1 and Bcl-2 (34). Such interaction appears to
target Raf-1 to mitochondria, where it may function to
promote survival of growth factor–deprived cells, perhaps
by phosphorylating and inactivating BAD (35). However,
the physical interaction between Raf-1 and Bcl-2 was not
confirmed in a more recent study (36).
In this report, we further assessed the role of BCR/ABL
in the cellular responses to growth factor deprivation as the
apoptotic stimulus. We demonstrate that Raf-1 kinase is
constitutively localized to mitochondria in BCR/ABL-
expressing cells, regardless of the presence of growth factors
in the culture medium. Moreover, an intact BCR portion
in p185 BCR/ABL is necessary for the mitochondrial lo-
calization of Raf-1 in IL-3–deprived BCR/ABL-expressing
cells. This correlates with the inability of p185
 
D
 
BCR-express-
ing cells to survive upon IL-3 deprivation. Furthermore,
the introduction of a mitochondria-targeted active form of
Raf-1 into p185
 
D
 
BCR-expressing cells restores antiapop-
totic function in vitro and leukemogenic potential in vivo.
 
Materials and Methods
 
Expression Vectors.
 
Plasmids LXSP/Mas70/Raf and LXSP/
Mas70/Raf K375W, containing the Mas70p TM domain (resi-
dues 1–30; reference 37) fused to the COOH-terminal region
(amino acids 301–648) of Raf-1 (
 
D
 
1-300), were obtained as fol-
lows: (
 
a
 
) pcDNA3-Raf-1 and pcDNA3-Raf-1 (K375W) (gift of
Dr. D. Morrison, National Cancer Institute, Frederick Cancer
Research and Development Center, Frederick, MD) were used as
templates for PCR amplification of wild-type and mutant Raf-1
using a forward primer (5
 
9
 
-CCAACAGGCTGGTCACAGC-
CGAAA-3
 
9
 
) and a reverse primer (5
 
9
 
-GAATTCGAATTC
GCTTCTCTGAAAACATG-3
 
9
 
) containing two BamHI sites
(
 
underlined
 
) in tandem; (
 
b
 
) an oligonucleotide encoding the
Mas70p TM domain was synthesized immediately downstream of
a XhoI restriction site; and (
 
c
 
) the PCR fragments and the
Mas70p TM double-stranded oligonucleotide were ligated into
the XhoI/BamHI-digested and dephosphorylated LXSP retrovi-
ral vector. Correct orientation and frame of both constructs was
confirmed by DNA sequence analysis.
pSR
 
a
 
 p185BCR/ABL, pSR
 
a
 
 Y77F/R552L/Y793F p185BCR/
ABL, pSR
 
a
 
 K671R p185BCR/ABL, and pSR
 
aD
 
176-426
p185BCR/ABL were obtained from Dr. A.M. Pendergast (Duke
University Medical Center, Durham, NC).
 
Electroporation.
 
The murine IL-3–dependent 32Dcl3 mye-
loid precursor cell line (38) was maintained at 37
 
8
 
C in IMDM-
CM (IMDM supplemented with 10% heat-inactivated fetal bo-
vine serum [FBS], 2 mM 
 
l
 
-glutamine, penicillin/streptomycin
(100 
 
m
 
g/ml each), and 15% WEHI-conditioned medium [WEHI-
CM] as a source of IL-3). Plasmids were introduced into 32Dcl3
cells by electroporation (200 mV, 960 
 
m
 
F; gene pulser, BioRad
Labs., Hercules, CA). BCR/ABL-expressing clones were ob-
tained after selection in G418-containing medium (1 mg/ml) and
were maintained in IMDM-CM. Mitochondria-targeted (M)-
Raf–expressing clones were selected in puromycin (2.5 
 
m
 
g/ml)
containing IMDM-CM.
 
Western Blot Analyses and Immunoprecipitation.
 
Western blots
were performed using anti–Raf-1, anti-Bax, anti-BAD, anti–Bcl-
X
 
L
 
, anti-ERK2 (all from Santa Cruz Biotechnology, Santa Cruz,
CA), antiphosphotyrosine (4G10; Upstate Biotechnology, Lake 
1997
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Placid, NY) anti–Bcl-2, anti-HSP90 (Transduction Laboratories,
Lexington, KY), anti–cytochrome oxidase (COX) IV (Molecular
Probes, Inc., Eugene, OR), and anti–BAG-1 (gift of Dr. J.C.
Reed) antibodies. Immunoprecipitations of Raf-1, ERK2, Ras
and BCR/ABL were carried out using anti-Raf-1, anti-ERK2,
anti-Ras (all from Santa Cruz Biotechnology) and anti-ABL anti-
body (Oncogene Science, Cambridge, MA), respectively.
 
BAD Phosphorylation.
 
Parental and BCR/ABL-expressing
cells were washed three times in phosphate-free RPMI medium
(GIBCO BRL, Gaithersburg, MD) and incubated in the same
medium for 3 h. Cells were then resuspended in phosphate-free
RPMI medium containing 0.3 mCi/ml of [
 
32
 
P]orthophosphate
(New England Nuclear, Boston, MA), 0.1% BSA, and 25 mM
Hepes (pH 7.4), and incubated for 3 h. Cells were fractionated
(see below, 
 
Preparation of Subcellular Fractions
 
) and cytoplasmic
fractions were precleared with preimmune serum and protein
A–sepharose (Pharmacia, Piscataway, NJ). Endogenous BAD was
immunoprecipitated with an anti-BAD polyclonal antibody
(C20; Santa Cruz Biotechnology), previously coated with protein
A–sepharose. Immunoprecipitates were resolved on a 12.5%
polyacryamide gel, transferred to nitrocellulose filters, and exposed.
 
Enzyme Assays.
 
RAS activation was determined by measur-
ing GTP-bound RAS as described (39). In brief, cells were
washed in phosphate-free RPMI medium (ICN Pharmaceuticals
Inc., Costa Mesa, CA) and incubated for 1 h in the same medium
supplemented with 0.1% BSA (Sigma Chemical Co., St. Louis,
MO), 25 mM Hepes (pH 7.4), and 2 mM 
 
l
 
-glutamine. Cells
were suspended in phosphate-free RPMI containing 0.25 mCi/
ml [
 
32
 
P]orthophosphate (New England Nuclear) and incubated at
37
 
8
 
C for 3 h. Cells were lysed in 1 ml of buffer containing 1%
Triton X-100, 50 mM Hepes (pH 7.4), 1.0 mg/ml BSA, 5 mM
MgCl
 
2
 
, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, 10 mM benza-
midine, 1 mM PMSF, and 0.2 mM sodium orthovanadate. Nu-
clei were pelleted by centrifugation (4 min, 12,000 
 
g
 
) and the re-
maining cell extract was solubilized in 1% Triton X-100, 50 mM
Hepes, pH 7.4, 0.5% sodium deoxycholate, 1.0 mg/ml BSA, 0.5 M
NaCl, 5 mM MgCl
 
2
 
, 10 
 
m
 
g/ml leupeptin, 10 mM benzamidine,
1 mM PMSF, and 0.2 mM sodium orthovanadate. Lysates were
incubated with anti-RAS antibody-coated agarose beads (Santa
Cruz Biotechnology) at 4
 
8
 
C for 1.5 h. Immunoprecipitates were
washed with a buffer containing 50 mM Hepes (pH 7.4), 0.5 M
NaCl, 5 mM MgCl
 
2
 
, 0.1% Triton X-100, 0.005% SDS, and 
 
32
 
P-
containing GTP/GDP were eluted with 2 mM EDTA, 5 mM
dithiothreitol (DTT), 0.2% SDS, 0.5 mM GDP, and 0.5 mM
GTP at 68
 
8
 
C for 20 min. Samples were resolved by thin-layer
chromatography, using 0.75 M KH
 
2
 
PO
 
4
 
 and visualized by auto-
radiography. The ratio of GTP-RAS to GTP 
 
1
 
 GDP-RAS was
determined by liquid scintillation counting.
The in vitro Raf-1 kinase assay was performed as described
(40). In brief, cells were lysed in 10 mM Hepes–150 mM NaCl,
1% NP-40, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, 10 mM
benzamidine, 1 mM PMSF, and 0.2 mM orthovanadate. Extracts
were precleared using protein A–agarose beads (Oncogene Science)
and then incubated with anti–Raf-1 antibody conjugated with
protein A–agarose beads at 4
 
8
 
C for 2 h. Immunoprecipitates, washed
four times with lysis buffer and once with kinase buffer (30 mM
Hepes, pH 7.4, 1 mM DTT, 10 mM MgCl
 
2
 
, 10 mM MnCl
 
2
 
, and
15 
 
m
 
M ATP), were incubated at room temperature for 20 min in
kinase buffer supplemented with 20 
 
m
 
Ci
 
g
 
-[
 
32
 
P]ATP and 5 
 
m
 
g his-
tone H1 as substrate. The reactions were ended by adding equal
volumes of gel loading buffer (4% SDS, 80 mM DTT, and 10%
glycerol). Samples were resolved by SDS-PAGE and the phos-
phoproteins were visualized by autoradiography.
MAP kinase (MAPK) activity was evaluated in an in vitro ki-
nase assay with anti–ERK-2 immunoprecipitates in kinase buffer
(30 mM Hepes, pH 7.4, 1 mM DTT, 10 mM MgCl
 
2
 
, and 15
 
m
 
M ATP), supplemented with 20 
 
m
 
Ci
 
g
 
-[
 
32
 
P]ATP and 2.5 
 
m
 
g
myelin basic protein (MBP) as substrate (40a). Reactions were
carried out at 37
 
8
 
C for 30 min and phosphoproteins were de-
tected as described above.
BCR/ABL kinase activity was determined using 5 
 
m
 
g of eno-
lase as substrate and anti-Abl immunoprecipitates from parental
32Dcl3 cells and wild-type or mutant BCR/ABL-expressing
cells. Kinase reactions were carried out as described (13).
 
Cell Viability and Apoptosis Assays.
 
Relative numbers of via-
ble cells were estimated by trypan blue exclusion assay. Apoptosis
was evaluated by flow cytometry determination of DNA content
in propidium iodide–stained nuclei (41).
 
Preparation of Subcellular Fractions.
 
Subcellular fractionation was
performed as described (35). In brief, cells were lysed in hypo-
tonic buffer (5 mM Tris, pH 7.4, 5 mM KCL, 1.5 mM MgCl
 
2
 
,
0.1 mM EGTA [pH 8.0], 1 mM DTT, 10 
 
m
 
g/ml aprotinin, 10
 
m
 
g/ml of leupeptin, 10 mM benzamidine, 1 mM PMSF, and
0.2 mM sodium orthovanadate) at 4
 
8
 
C for 30 min. After homog-
enization (20–30 strokes with a Dounce homogenizer B pestle),
samples were centrifuged (2,500 
 
g
 
 for 5 min) to remove the nu-
clei, and centrifuged again (12,000 
 
g
 
 for 30 min) to obtain the
heavy membrane (HM) fraction (pellet). The supernatants were
centrifuged at 150,000 
 
g
 
 for 1.5 h to obtain light membrane (LM)
and cytoplasmic (C) fractions. The HM and LM fractions were
solubilized in Triton X-100, 10 mM Tris-HCl (pH 7.4), 150
mM NaCl, 5 mM EDTA, 10 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupep-
tin, 10 mM benzamidine, 1 mM PMSF, and 0.2 mM sodium
orthovanadate.
 
Leukemogenesis in SCID Mice.
 
5–7-wk-old male SCID mice
(Taconic Farms, Inc., Germantown, NY) were injected intrave-
nously with 5 
 
3
 
 10
 
6
 
 cells/transfectant (10 mice/group), and 3 wk
later organs were analyzed for the presence of leukemia. Tissue
sections from bone marrow, spleen, lung, liver, kidney, and brain
were fixed in phosphate-buffered formalin and embedded in par-
affin blocks. Two levels of each block were cut and slides were
stained with hematoxylin and eosin.
 
Results
 
An Intact BCR Segment Is Required for the Antiapoptosis
Function of BCR/ABL.
 
Although a functional BCR/ABL
tyrosine kinase is absolutely required for protection from
apoptosis (13), the consequences of disrupting other do-
mains or mutating residues important for BCR/ABL-
dependent signaling are much less severe, unless multiple
residues are involved (13). One exception is the p185
 
D
 
BCR
mutant, which lacks 251 amino acids (176 to 426) of the
BCR domain and is reportedly defective in protecting
growth factor–dependent cells from apoptosis induced by
IL-3 withdrawal (13). To investigate mechanisms associ-
ated with apoptosis susceptibility upon disruption of the
BCR portion of the BCR/ABL oncoprotein, growth fac-
tor–dependent 32Dcl3 myeloid precursor cell derivatives
were established by electroporation of plasmids carrying ei-
ther wild-type BCR/ABL (p185WT) or a mutant lacking
amino acids 176–426 of the BCR portion (p185
 
D
 
BCR).
Selected clones of the transfected cells expressed compara-
ble levels of wild-type and mutant BCR/ABL protein (Fig. 
1998
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1 
 
A
 
); moreover, the ectopically expressed proteins were
similarly potent in their tyrosine kinase activity, as indi-
cated by phosphorylation of the enolase substrate by anti-
ABL immunoprecipitates (Fig. 1 
 
B
 
). Upon IL-3 depriva-
tion, parental cells lost viability very rapidly and were all
dead after 48 h; p185WT-expressing cells were all viable,
whereas a marked decrease in the frequency of viable cells
was noted in the p185
 
D
 
BCR cell cultures after a 48-h IL-3
deprivation (data not shown). Loss of viability in cultures of
parental and p185
 
D
 
BCR-expressing cells was due to apop-
tosis, as indicated by flow cytometry detection of cells with
hypodiploid DNA content (Fig. 1 
 
C).
Activation of the Ras-Raf-MAPK Pathway in p185WT- and
p185DBCR-expressing Cells. Expression of BCR/ABL
leads to constitutive activation of RAS (42, 39, 13), and ap-
optosis of BCR/ABL-expressing cells is induced upon
conditional expression of dominant-negative RAS (30). To
determine whether p185DBCR-expressing cells can acti-
vate the Ras-Raf-MAPK pathway, we analyzed RAS acti-
vation by direct examination of RAS-GTP levels. In pa-
rental 32Dcl3 cells, RAS was detected in the GTP-bound
form only upon culture with IL-3–supplemented medium,
whereas both p185WT- and p185DBCR-expressing cells
displayed constitutive levels of RAS activation, although
the relative amount of RAS-GTP in p185DBCR-express-
ing cells was somewhat lower than that in p185WT-express-
ing cells (Fig. 2 A). To determine whether the activation of
RAS by p185DBCR correlated with that of RAS down-
stream effectors in the MAPK pathway, the levels of Raf-1
activity were analyzed by in vitro kinase assay, using his-
Figure 1. (A) Expression of BCR/ABL proteins in 32Dcl3 cell clones. 32Dcl3 cells were electroporated with the pSRa constructs encoding the indi-
cated BCR/ABL proteins. Western blots show expression of wild-type or mutant BCR/ABL protein in representative clones. Levels of HSP90 were de-
tected as control for protein loading. (B) In vitro kinase activity of wild-type (p185WT) and mutant (p185DBCR) BCR/ABL. Phosphorylation of eno-
lase (5 mg) used as a substrate was examined in anti-ABL immunoprecipitates from parental and BCR/ABL-expressing 32Dcl3 cells. Wild-type and
mutant BCR/ABL were detected in the immunoprecipitates by Western blot with the Ab-3 anti-ABL antibody. Low levels of c-abl expression in
32Dcl3 immunoprecipitates were detected only after long exposure. (C) Apoptosis in cultures of IL-3–deprived parental and BCR/ABL-expressing
32Dcl3 cells. Apoptotic cells were evaluated cytometrically (propidium iodide staining) in cells cultured in the absence of IL-3–containing medium for 24
and 48 h. Representative of three independent experiments with similar results.
Figure 2. RAS, RAF, and MAPK
activation in BCR/ABL-expressing
32Dcl3  cells. (A) GTP-bound RAS was
measured as described (39) using serum–
and IL-3–starved (5 h) BCR/ABL-
expressing cells. (B) c-Raf-1 activity was
measured as described (40) using histone
H1 as substrate. (C) c-Raf-1 tyrosine
phosphorylation in BCR/ABL-express-
ing cells. Tyrosine phosphorylated c-Raf-1
was detected by antiphosphotyrosine
blotting of anti–c-Raf-1 immunoprecip-
itates from BCR/ABL-expressing cells.
(D) MAPK activity was measured as de-
scribed (51), using MBP as substrate.
Representative of three independent ex-
periments.1999 Salomoni et al.
tone H1 as substrate. After starvation, low levels of Raf-1
activity were detected in parental cells, higher levels were
found in p185DBCR cells, and p185WT cells showed the
highest Raf-1 activity (Fig. 2 B). A decrease in the level of
Raf-1 expression was noted in IL-3–starved 32Dcl3 cells,
consistent with a previous report (31). Since tyrosine phos-
phorylation of Raf-1 is postulated as an important mechanism
for RAF activation (43), we assessed RAF phosphorylation
using antiphosphotyrosine immunoblotting of anti-RAF
immunoprecipitates (Fig. 2 C), and by phosphoaminoacid
analysis (data not shown). Both assays revealed equal levels
of RAF tyrosine phosphorylation in p185WT- and in
p185DBCR-expressing cells.
One effect of Raf-1 activation is the induction of MAPK
kinase kinase activity, which in turn activates the MAPK.
MAPK activity is dependent on growth factor stimulation
and provides an index of the proliferative capacity of the
cell. Thus, we analyzed the levels of activation of MAPK
by in vitro kinase assay, using MBP as substrate. In parental
32Dcl3 cells, withdrawal of IL-3 was associated with
downregulation of MAPK activity, whereas in p185WT-
expressing cells, levels of activation were similar to those in
parental 32Dcl3 cells growing in the presence of IL-3. In
p185DBCR-expressing cells, activation of MAPK was ap-
proximately twofold lower than in p185WT-expressing
cells, but clearly higher than in starved parental cells. Thus,
IL-3–deprived p185DBCR-expressing cells retain the abil-
ity to activate the Ras-Raf-MAPK pathway, but the acti-
vation of each of these signal transducing molecules is less
robust than in cells carrying wild-type BCR/ABL.
Expression of Anti- and Proapoptosis Proteins in p185DBCR-
expressing Cells. Activation, albeit at a reduced level, of
the Ras-Raf-MAPK pathway in p185DBCR-expressing
cells suggests that the enhanced susceptibility of these cells
to apoptosis involves the disruption of other signaling path-
ways required for cell survival. Since enhanced expression
of Bcl-2 is induced by BCR/ABL expression in hemato-
poietic cells (15), expression levels of several proapoptotic
(Bax and BAD) and antiapoptotic proteins (BAG-1, Bcl-
XL, and Bcl-2) were compared in parental and BCR/ABL-
expressing cells. In parental 32Dcl3 cells, the expression of
Bax, BAG-1, and Bcl-XL was not affected by IL-3 depriva-
tion (data not shown), whereas Bcl-2 levels were clearly di-
minished and BAD was detected at lower levels and only in
its fast-migrating (presumably due to hypophosphoryla-
tion), proapoptotic form (Fig. 3 A). In p185WT-expressing
cells, Bcl-2 and BAD levels were enhanced, but the latter
was detected predominantly in its slow-migrating, non-
functional form (Fig. 3 A). Compared to p185WT-express-
ing cells, p185DBCR-expressing cells showed markedly
decreased Bcl-2 levels; moreover, BAD was expressed in its
fast-migrating, proapoptotic form (Fig. 3 A). BAD phos-
phorylation was directly assessed in anti-BAD immunopre-
cipitates from cells metabolically labeled with [32P]ortho-
phosphate. As shown in Fig. 3 B, BAD phosphorylation
was induced upon IL-3 treatment of parental 32Dcl3 cells
and was constitutive in cells expressing wild-type BCR/
ABL, but was not detectable in p185DBCR-expressing cells.
Together, these results suggest that an intact BCR domain
is necessary for a BCR/ABL-dependent pathway that main-
tains elevated levels of Bcl-2 and promotes BAD phosphor-
ylation.
BCR/ABL Induces the Constitutive Localization of Raf-1 to
Mitochondria. Previous studies have suggested that Raf-1
is a potential regulator of the apoptotic pathway because of
its coimmunoprecipitation with Bcl-2 and its localization
to mitochondria (34, 35, 44). Moreover, Raf-1 appears to
protect 32Dcl3 cells from apoptosis induced by IL-3 depri-
vation if constitutively expressed in the mitochondria (35).
Thus, we investigated whether Bcl-2 expression correlates
with levels of mitochondrial Raf-1 in parental and BCR/
ABL-expressing cells. By subcellular fractionation and
Western blot analysis, low levels of Raf-1 were detected in
mitochondrial and membrane fractions (HM and LM, re-
Figure 3. (A) Expression of anti- and proapoptosis proteins in BCR/
ABL-expressing cells. Western blots show expression of BAD and Bcl-2
proteins in parental and BCR/ABL-expressing 32Dcl3 cells. Cells were
starved of IL-3–containing medium for 16 h. (B) Phosphorylation of
BAD in BCR/ABL-expressing cells. Parental and BCR/ABL-expressing
cells were starved from both IL-3 and serum (3 h) in [32P]orthophos-
phate-containing medium for 3 h. After starvation, parental cells were ei-
ther stimulated for 30 min with IL-3 (150 mg/ml) and 0.1% FBS or left
untreated. The arrow indicates phosphorylated BAD (z24 kD). As con-
trol, labeled extracts were incubated with preimmune serum and protein
A–sepharose beads (PRE). Representative of two different experiments.2000 Role of Mitochondrial Raf in BCR/ABL Leukemogenesis
spectively) of parental 32Dcl3 cells cultured in the presence
of IL-3 (Fig. 4 A). After IL-3 removal, Raf-1 protein was
no longer detectable in the mitochondrial fraction of paren-
tal cells or of p185DBCR-expressing cells, but was readily de-
tectable in the mitochondrial fraction of IL-3–starved
p185WT-expressing cells (Fig. 4 A). The levels of mito-
chondrial Raf-1 in parental and BCR/ABL-expressing
32Dcl3 cells were correlated well with those of Bcl-2. In
IL-3–deprived parental cells, the decline of mitochondrial
Bcl-2 expression correlated with the decrease in Bcl-2 lev-
els observed in total lysates (Fig. 3). In p185WT-expressing
cells, levels of mitochondrial Bcl-2 were similar to those
detected in parental cells growing in the presence of IL-3,
whereas in p185DBCR-expressing cells, Bcl-2 levels were
comparable with those observed in growth factor–starved
32Dcl3 cells (Fig. 4 B).
Mitochondrial Targeting of Constitutively Active Raf-1 Res-
cues p185DBCR-expressing Cells from Apoptosis Induced by IL-3
Deprivation. In p185DBCR-expressing cells, Raf-1 was not
detectable in the mitochondria, likely as a consequence of
the reduced expression of Bcl-2; however, it is unclear
whether lack of mitochondrial Raf-1 expression and sus-
ceptibility of p185DBCR-expressing cells to apoptosis are
causally linked. To address this issue, we generated an ex-
pression plasmid in which human Raf-1 was fused with the
transmembrane domain of the yeast outer mitochondrial
membrane protein MAS70p (37). Moreover, to prevent
Raf-1 targeting to the plasma membrane and to obtain a
constitutively active mutant, we deleted the NH2-terminal
domain of Raf-1, which mediates binding to Ras and is
known to exert a negative regulatory function (45). After
transfection of p185DBCR cells, ectopic expression of
M-Raf was detected by Western blot either in total lysates
(Fig. 5 A), or in the mitochondrial fraction of selected
clones (Fig. 5 B). Indeed, M-Raf was highly expressed and
restricted to the mitochondrial fraction. As expected, the
decrease in Bcl-2 levels detected in the mitochondrial frac-
tion of IL-3–starved p185DBCR-expressing cells (com-
pared to p185WT cells, Fig. 4 B) was not reversed by ec-
topic expression of M-Raf (Fig. 5 C). By contrast, ectopic
expression of M-Raf induced hyperphosphorylation of
BAD (Fig. 5 C) and its release from the mitochondria into
the cytosol (Fig. 5 D). Analysis of the kinetics of cell death,
upon IL-3 removal, in p185DBCR-expressing cells and in
selected clones expressing p185DBCR and constitutively
active M-Raf indicated that p185DBCR/M-Raf–express-
ing cells were protected from apoptosis induced by IL-3
deprivation (Fig. 6). Moreover, these cells were able to
proliferate in the absence of IL-3 (data not shown). These
experiments support the hypothesis that the apoptosis sus-
ceptibility of p185DBCR-expressing cells is causally linked
to the inability of the p185DBCR mutant to induce mito-
chondrial targeting of Raf-1. To determine whether the
expression of constitutively active M-Raf specifically res-
cues p185DBCR-expressing cells from apoptosis or whether
32Dcl3 cells expressing other BCR/ABL mutants defective
in apoptosis protection can be rescued as well, the effect of
M-Raf was studied on cells expressing either a kinase-defi-
cient mutant (K671R) or a triple mutant (Y177F/R552L/
Y793F) lacking a functional phosphotyrosine binding motif
in the SH2 domain, and GRB2 binding and autophosphor-
ylation sites. Ectopic expression of M-Raf in both cell
transfectants (Fig. 7 A) induced only a modest protection
from cell death after 24 h, similar to that observed in paren-
tal cells expressing M-Raf (compare Fig. 7, B and C).
Moreover, after 48 h, ,10% of the transfected cells were
viable (Fig. 7 C).
Mitochondrial Targeting of Constitutively Active Raf-1 Res-
cues the Leukemogenic Potential of p185DBCR-expressing Cells.
To determine whether expression of constitutively active
Figure 4. c-Raf-1 and Bcl-2 expression in subcellular fractions of parental and BCR/ABL-expressing 32Dcl3 cells. (A) Western blots show c-Raf-1
levels in fractions enriched for mitochondria (HM), cytoplasmic membrane (LM), and cytoplasm (C) from parental and BCR/ABL-expressing cells. Cells
were starved of IL-3–containing medium for 16 h. (B) Western blots show Bcl-2 levels in the mitochondrial fraction of parental and BCR/ABL-express-
ing cells cultured as described above. Levels of the subunit IV of mitochondrial COX were measured as control of equal loading.2001 Salomoni et al.
Raf-1 in the mitochondria can activate a survival pathway
required for the leukemia-inducing effect of BCR/ABL,
immunocompromised SCID mice (10–15/group) were in-
jected with an equal number (5 3 106/mouse) of 32Dcl3
cells expressing wild-type BCR/ABL, the p185DBCR
mutant, or coexpressing p185DBCR and constitutively ac-
tive M-Raf. As an additional control, mice were also in-
jected with 32Dcl3 cells expressing the constitutively active
M-Raf. 3 wk after cell injection, various organs from the
SCID mice (three per group) were evaluated by visual in-
spection and light microscopy (Fig. 8). As expected, injec-
tion of wild-type BCR/ABL-expressing cells resulted in
splenomegaly and development of myelogenous leukemia
that involved several organs. The spleen showed acute my-
elogenous leukemia (AML) without overt maturation.
AML focally involved the liver and other nonhematopoi-
etic organs such as kidneys and meninges. The bone mar-
row showed focal areas of blast accumulation, but most
marrow cells exhibited features of initial granulocytic dif-
ferentiation. Essentially normal organ histology was seen in
the mice injected with p185DBCR-expressing cells, except
for splenic extramedullary hematopoiesis, congestion, and
iron deposition; no overt leukemia was seen in any of the
organs. In contrast, injection of 32Dcl3 cells coexpressing
the nononcogenic p185DBCR mutant and the constitu-
tively active mitochondrial Raf-1 resulted in mild to mod-
erate splenomegaly in all three mice tested. Hematoxylin
and eosin–stained sections demonstrated patchy to diffuse
involvement of the spleens by poorly differentiated AML.
AML also involved livers (two of three animals), kidneys,
Figure 5. (A) RAF expression
in total extracts of p185DBCR/
M-Raf transfectants. Western
blot shows expression of endoge-
nous and mitochondria-targeted
Raf-1 in total extracts of selected
clones. (B) RAF expression in
subcellular extracts of p185DBCR/
M-Raf transfectants. Western blot
shows expression of endogenous
(Raf-1) and mitochondria-targeted
(M-Raf) Raf-1 in subcellular ex-
tracts from p185DBCR/M-Raf
selected clones. Levels of the sub-
unit IV of mitochondrial COX
and of HSP90 were measured as
control of equal loading and of
appropriate subcellular fraction-
ation. (C) Bcl-2 and BAD ex-
pression in total cell lysate of
p185DBCR– and p185DBCR/
M-Raf–expressing  cells. (D) BAD
expression in subcellular fractions
of p185WT–, p185DBCR–, and
p185DBCR/M-Raf–expressing
cells. Western blots show BAD
expression in mitochondria- (HM),
cytoplasmic membrane– (LM),
and cytoplasm- (C) enriched frac-
tions. Arrows, hypo- and hyper-
phosphorylated BAD. Cells were
starved of IL-3–containing me-
dium for 16 h. Levels of the sub-
unit IV of mitochondrial COX
and of HSP90 were measured as
control of equal loading and of
appropriate subcellular fraction-
ation.
Figure 6. Viability of p185DBCR/M-Raf transfectants in IL-3–deprived
cultures. Numbers of viable cells from triplicate wells were estimated for
each transfectant at the indicated times by trypan blue exclusion assay.
Representative of three independent experiments.2002 Role of Mitochondrial Raf in BCR/ABL Leukemogenesis
and meninges. Bone marrows showed either CML-like
myeloproliferation with various degrees of fibrosis or an
overt AML. Although abnormal, the bone marrows usually
demonstrated a higher degree of myeloid maturation than
other organs. Leukemic infiltrates in all the organs appeared
similar to those in mice injected with cells expressing wild-
type BCR/ABL, although the extent of the disease was
less. Injection of parental 32Dcl3 cells (data not shown) or
32Dcl3 cells expressing M-Raf only (Fig. 8) did not lead to
development of leukemia. These differences in histopatho-
logic findings were reflected in the survival of the various
groups; mice (10/group) injected with parental 32Dcl3
cells, p185DBCR–, and M-Raf–expressing cells never de-
veloped leukemia, whereas mice (10 and 15 [five/each
clone]) injected with p185WT– and p185DBCR/M-Raf–
expressing cells died of leukemia 4–6 and 6–9 wk after in-
jection, respectively (Fig. 9).
A Dominant Negative Raf-1 Targeted to Mitochondria Induc-
es Apoptosis in p185WT Cells. To further demonstrate the
importance of mitochondrial expression of a functional
Raf-1 in BCR/ABL-mediated leukemogenesis, a domi-
nant-negative Raf-1 mutant (K375W) was targeted to the
mitochondria and assessed for its ability to induce apoptosis
of IL-3–deprived p185WT-expressing 32Dcl3 cells. Upon
IL-3 deprivation, expression of the mitochondria-targeted
M-Raf (K375W) mutant (Fig. 10 A) slightly reduced the
viability of p185WT-expressing cells (Fig. 10 B). However,
the effect became more pronounced when cells were de-
prived of both IL-3 and serum (Fig. 10 C). After 24 h,
z65% of p185WT/M-Raf (K375W) cells were dead,
whereas  ,20% of p185WT-expressing cells were dead. A
similar difference in the viability of the transfected cells was
observed after 48 h in IL-3– and serum–starved cultures
(Fig. 10 C).
Discussion
Reduced susceptibility to apoptosis is one of the charac-
teristics of BCR/ABL-expressing cells. Although this prop-
erty is especially manifested by growth factor–dependent
hematopoietic cell lines ectopically expressing BCR/ABL
and by CML cells in blast transformation (11, 13, 46), pro-
genitor cells from CML in chronic phase also exhibit a pro-
longed survival in serum-free cultures (12). By contrast,
growth factor–independent proliferation and differentiation
arrest are typical features of BCR/ABL-expressing hemato-
poietic cell lines and CML-blast crisis cells, but not of
CML-chronic phase progenitors (47). Thus, enhanced cell
survival, rather than proliferative advantage, might be the
primary and most direct consequence of BCR/ABL ex-
pression in hematopoietic progenitor cells.
The mechanisms underlying BCR/ABL-dependent pro-
tection from apoptosis induced by growth factor depriva-
Figure 7. (A) BCR/ABL and RAF expression in 32Dcl3 cells express-
ing a kinase-deficient or triple mutant p185BCR/ABL. Western blots
show expression of mutant BCR/ABL (KD, K671R kinase deficient;
TM, Y177F/R552L/Y793F triple mutant) and RAF (endogenous and
mitochondria targeted) in a representative clone per each transfectant.
Levels of HSP90 were determined as control for protein loading. (B and
C) Viability of mutant (KD and TM) p185BCR/ABL- and mutant (KD
and TM) p185BCR/ABL/M-Raf transfectants in IL-3–deprived cultures.
Numbers of viable cells from triplicate wells were estimated for each
transfectant at the indicated times by trypan blue exclusion assay. Repre-
sentative of three independent experiments using four different clones per
each transfectant.2003 Salomoni et al.
tion and by other death-inducing stimuli are not well un-
derstood. A functional tyrosine kinase is an absolute
requirement for apoptosis protection (13), and recent data
also suggest that disruption of RAS activity promotes apop-
totic cell death of BCR/ABL-expressing myeloid precursor
cells (30). Moreover, BCR/ABL activates the Akt serine/
threonine kinase (48), which promotes survival in many
cell types by phosphorylation and consequent inactivation
of the proapoptotic BAD (49, 50) and, at least in hemato-
poietic cells, by enhancing Bcl-2 expression (48, 51). In-
creased Bcl-2 levels in BCR/ABL-expressing cells have
also been reported (15, 16); however, no information is
available about the mechanisms and pathways leading to
such an increase.
Mechanisms of Apoptosis Susceptibility in p185DBCR-express-
ing 32Dcl3 Cells. In addition to kinase-deficient BCR/ABL,
the  DBCR (176–426) BCR/ABL (p185DBCR) mutant
was also unable to protect transfected 32Dcl3 cells from ap-
optosis (reference 13, and this study). Apoptosis susceptibility
in 32Dcl3 cells expressing the p185DBCR mutant was asso-
Figure 8. Histologic findings in
mice injected with BCR/ABL–
M-Raf–, or BCR/ABL/M-Raf–
expressing 32Dcl3 cells. Tissue
sections from various organs
were fixed in phosphate-buffered
formalin, embedded in paraffin,
and stained with hematoxylin/
eosin. Representative micropho-
tographs from bone marrow,
spleen, and liver (original magni-
fication: 600) from groups of
three mice of each phenotype.2004 Role of Mitochondrial Raf in BCR/ABL Leukemogenesis
ciated with reduced Bcl-2 levels and expression of non-
phosphorylated, proapoptotic BAD. The reduced levels of
Bcl-2 expression in p185DBCR-expressing cells were not
due to a transcriptional mechanism since Bcl-2 mRNA
levels were not diminished (data not shown); on the other
hand, the rate of Bcl-2 synthesis was decreased and Bcl-2
half-life was shorter (data not shown), possibly explaining
the reduced Bcl-2 levels in p185DBCR-expressing cells.
The expression of nonphosphorylated, proapoptotic BAD
might reflect the reduced ability of the p185DBCR mutant
to activate the Akt serine/threonine kinase (48), which, in
turn, phosphorylates BAD (49, 50). However, it seems un-
likely that this is the only mechanism, since SH2 domain
BCR/ABL mutants are even less capable of Akt activation
than the p185DBCR mutant (48), and yet can protect
32Dcl3 cells from apoptosis much more efficiently (refer-
ence 13; and our unpublished results).
In addition to the changes in Bcl-2 and BAD,
p185DBCR-expressing cells also failed to express detect-
able levels of c-Raf-1 in the mitochondria. This might be
the consequence of the decrease in the levels of Bcl-2,
which has been shown to target c-Raf-1 to the mitochon-
dria (35); however, the undetectable expression of c-Raf-1
in the mitochondrial fraction of p185DBCR-expressing
cells contrasts with the reduced but readily detectable Bcl-2
levels, raising the possibility that BCR/ABL might regulate
the targeting of c-Raf-1 to mitrochondria in a Bcl-2-inde-
pendent manner.
Complementation of the p185DBCR-dependent Phenotype by
Constitutively Active Mitochondria-targeted c-Raf-1. In a re-
cent study (35), susceptibility of IL-3–deprived 32Dcl3
cells to apoptosis was alleviated by ectopic expression of
mitochondria-targeted, constitutively active c-Raf-1. In
our study, apoptosis susceptibility and leukemogenic po-
tential of p185DBCR-expressing cells were rescued by the
Figure 9. Survival curves of mice injected with BCR/ABL–, M-Raf–,
or BCR/ABL/M-Raf–expressing 32Dcl3. SCID mice were injected in-
travenously with 5 3 106 cells from parental or transfected 32Dcl3 cells.
10 mice were included in the parental, p185WT, p185DBCR (five mice
per two clones), and M-Raf (five mice per two clones) group, whereas 15
mice were included in the p185DBCR/M-Raf (five mice per three clones)
group.
Figure 10. (A) RAF expression in subcellular extracts of p185WT–
and p185WT/K375W M-Raf–transfected cells. Western blot shows ex-
pression of endogenous (Raf-1) and mitochondria-targeted (M-Raf) in
subcellular extracts of selected clones. Levels of the subunit IV of mito-
chondrial COX and of HSP90 were measured as control of equal loading
and of appropriate subcellular fractionation. (B and C) Viability of
p185WT BCR/ABL– and p185WT BCR/ABL/K375W M-Raf–express-
ing 32Dcl3 cells. Numbers of viable cells (triplicate wells per transfectant)
in IL-3– (B) or IL-3– and serum– (C) deprived cultures were estimated at
the indicated times by trypan blue exclusion assay. Representative of
three independent experiments.2005 Salomoni et al.
constitutively active M-Raf. Interestingly, apoptosis sus-
ceptibility of cells expressing a kinase-deficient (K671R)
BCR/ABL mutant or a triple mutant (Y177F/R552L/
Y793F) BCR/ABL defective in the SH2 domain function,
and in autophosphorylation and GRB-2 binding activity
was not rescued by M-Raf. These findings are most likely
explained by the severity of the apoptosis-susceptible phe-
notype of kinase deficient– and triple mutant–transfected
cells. In this regard, the Y177F/R552L/Y793F BCR/ABL
mutant retained its tyrosine kinase activity, but did not ac-
tivate RAS in transfected 32Dcl3 cells (13). Constitutively
active M-Raf did not exert strong antiapoptosis effects in
these cells, but was able to correct the apoptosis susceptibil-
ity of cells expressing the p185DBCR mutant which, in-
stead, is competent for Ras-Raf-1-MAP kinase activation.
Thus, RAS-dependent Raf-1/MAP kinase activation and
mitochondria-targeting of Raf-1 are independently regu-
lated by BCR/ABL, but are both necessary for protection
from apoptosis induced by growth factor deprivation. The
biological relevance of a BCR/ABL-dependent pathway of
mitochondrial Raf-1 targeting is also supported by the ob-
servation that expression of a mitochondria-targeted domi-
nant-negative Raf-1 in p185WT 32Dcl3 cells was associ-
ated with increased susceptibility to apoptosis, especially
evident in the absence of both IL-3 and serum. Susceptibil-
ity to apoptosis associated with expression of a dominant-
negative RAS was more pronounced (30), probably due to
the functional inhibition of both plasma membrane–associ-
ated and mitochondrial Raf-1.
Constitutively active M-Raf restored the leukemogenic
potential of p185DBCR-expressing cells, underscoring the
importance of the activation of antiapoptosis mechanisms in
BCR/ABL leukemogenesis. p185DBCR/M-Raf–expressing
cells were not only resistant to apoptosis induced by IL-3
deprivation, but were also able to proliferate, which may
explain their ability to induce leukemia in mice. Compared
to p185WT-expressing cells, p185DBCR/M-Raf–express-
ing cells caused a less bulky leukemia, but with similar
widespread organ distribution. This probably reflects the
reduced proliferation rate of p185DBCR/M-Raf–express-
ing cells, compared to p185WT-expressing cells. In vivo,
p185DBCR/M-Raf 32Dcl3 cells in liver and spleen did
not undergo differentiation, whereas these cells showed a
more differentiated morphology in the bone marrow, most
likely due to the exposure to more potent differentiation
stimuli in that microenvironment. However, there were no
detectable morphological differences between p185WT
and p185DBCR/M-Raf cells, suggesting that both wild-
type and mutant p185DBCR are equally potent in block-
ing hematopoietic differentiation, provided that an antiap-
optosis signal (M-Raf expression) permits the survival of
p185DBCR-expressing cells.
Potential Mechanisms of M-Raf Requirement in BCR/ABL
Leukemogenesis. The importance of antiapoptosis path-
ways in BCR/ABL tumorigenesis was first demonstrated in
a study showing that suppression of Bcl-2 expression inhib-
its the tumorigenic potential of wild-type BCR/ABL-express-
ing hematopoietic cells (15).
Our data further support the role of survival factors in
BCR/ABL leukemogenesis, but the mechanisms whereby
M-Raf expression promotes survival and favors the leuke-
mia-inducing effects of p185DBCR-expressing cells remain
unclear. Upon M-Raf expression in p185DBCR-express-
ing cells, Bcl-2 levels were unaffected, remaining identical
to those in cells expressing p185DBCR only. However,
M-Raf expression induced phosphorylation of BAD, con-
sistent with the results of a previous study (35) in which
phosphorylated BAD was detected in cells transiently trans-
fected with M-Raf. Moreover, phosphorylated BAD was
detected in the cytosolic fraction; this suggests that Raf-1–
dependent phosphorylation of BAD in the mitochondria
might serve as a “rescue” mechanism to inactivate proap-
optotic BAD that was not sequestered in the cytosol upon
phosphorylation and interaction with 14-3-3 (20). The role
of Raf-1 in BAD phosphorylation remains unclear; the ma-
jor sites of BAD serine phosphorylation in vivo are within a
motif recognized by Akt, and their phosphorylation is Akt
dependent as indicated by its inhibition in cells treated with
the PI-3k/Akt pathway inhibitor wortmannin or upon ex-
pression of dominant-negative Akt (49, 50). Moreover,
Akt phosphorylates BAD in vitro at the same sites phos-
phorylated in vivo. By contrast, Raf-1 appears to phosphor-
ylate BAD in vitro at sites distinct from those phosphory-
lated by Akt and required for the interaction with 14-3-3
(20).
Thus, M-Raf–dependent phosphorylation of BAD might
involve residues distinct from those phosphorylated by Akt,
yet resulting in the inhibition of the proapoptotic function
of BAD; alternatively, the serine residues of BAD that are
phosphorylated by Akt may also undergo Raf-1–dependent
phosphorylation in the mitochondria.
In conclusion, we have identified mitochondrial Raf-1
as an effector of BCR/ABL in apoptosis resistance and leu-
kemogenesis. An understanding of the precise mechanisms
whereby M-Raf is activated by BCR-ABL and promotes
cell survival awaits further experimentation.
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